A team of researchers conducted genetic analyses of children and adolescents with primary adrenal insufficiency of unknown etiology to provide insight into diagnosing this and other related conditions.
In patients with classical congenital adrenal hyperplasia, the use of modified-release hydrocortisone may improve biochemical control.
Adjusting threshold levels of 17-OHP to reflect gestational age and birth weight might be a safe and efficient strategy to improve screening for CAH in newborns.
Among girls with true central precocious puberty referred to a tertiary center in Israel, nonclassical congenital adrenal hyperplasia was diagnosed in almost 5% of patients.
A case report suggested that combination therapy with growth hormone and anastrozole may improve final height in congenital adrenal hyperplasia.
Chronocort was effective in treating congenital adrenal hyperplasia in a phase 2 trial.
Mortality rates are higher among patients with congenital adrenal hyperplasia.
